Skip to main navigation
  • News & Investors

    News & Investors

    • Press Releases
    • Financial Events
    • Scientific Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Analyst Coverage
    • Request Information
    • Investor FAQs
    • Investor Contact
  • Contact Us
Celsion
  • TECHNOLOGY
    • LTSL
    • TheraPlas
    • TheraSilence
  • PRODUCTS
    • ThermoDox
    • GEN-1
  • PIPELINE
    • Clinical Studies
    • Pre-clinical Programs
  • DISEASES
  • PUBLICATIONS
  • ABOUT US
    • Leadership
    • Board of Directors
    • Corporate Governance
Select Page

Stock Ownership

    Investor Relations

    • News & Investors
    • Press Releases
    • Financial Events
    • Scientific Presentations
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
      • Insider Transactions
      • Stock Ownership
    • Financial Information
    • Stock Information
    • Analyst Coverage
    • Request Information
    • Investor FAQs
    • Investor Contact

Stock Ownership

Name Relationship/Title Total Held
CHURCH JEFFREY WAYNE CFO 54,298
Fritz Frederick J. Director 51,491
Martinez Alberto R Jr Director 45,000
Tardugno Michael H Director, Chairman, President and CEO 187,700
Tumminello Timothy J Controller 15,258

For recent transactions, including derivative transactions, see our Section 16 SEC filings page.

    Shareholder Tools

    • Printed Materials
    • Email Alerts
    • Downloads
    • RSS
    • Print
    • Search

    • Facebook
    • Google
    • LinkedIn
    • Twitter
    • RSS

Home

Technology

Products

Pipeline

Disease

Publications

News & Investors

About Us

Careers

Privacy Policy

    ThermoDox is a registered trademark of Celsion Corporation.
    TheraPlas and TheraSilence are trademarks of Celsion Corporation.
    Avastin is a registered trademark of Genentech, Inc.
    Copyright © 2021 Celsion Corporation. All rights reserved.

    Share This
    • Twitter
    • Google+
    • Facebook
    • LinkedIn